| Q2 2024 |
8 |
$103M |
+$8.61M |
-$5.82M |
+$2.79M |
NTRA, GH, AKYA, CDNA, TXG
|
13F-HR |
8/9/2024, 12:57 PM |
| Q1 2024 |
8 |
$106M |
+$14.1M |
-$20.4M |
-$6.26M |
NTRA, AKYA, GH, TXG, QTRX
|
13F-HR |
5/15/2024, 04:37 PM |
| Q4 2023 |
9 |
$114M |
+$32.5M |
-$32.8M |
-$316K |
NTRA, AKYA, GH, TMO, TXG
|
13F-HR |
2/14/2024, 04:24 PM |
| Q3 2023 |
6 |
$102M |
+$1.76M |
-$7.27M |
-$5.51M |
NTRA, AKYA, GH, ADPT, NSTG
|
13F-HR |
11/14/2023, 04:34 PM |
| Q2 2023 |
9 |
$148M |
+$36.9M |
-$27.8M |
+$9.12M |
NTRA, AKYA, GH, ADPT, NSTG
|
13F-HR |
8/14/2023, 05:34 PM |
| Q1 2023 |
8 |
$151M |
+$13.5M |
-$10.6M |
+$2.87M |
NTRA, ADPT, AKYA, MXCT, GH
|
13F-HR |
5/15/2023, 04:20 PM |
| Q4 2022 |
8 |
$149M |
+$18.1M |
-$26.9M |
-$8.82M |
NTRA, GH, ADPT, AKYA, MXCT
|
13F-HR |
2/14/2023, 08:14 AM |
| Q3 2022 |
9 |
$219M |
+$39.8M |
|
+$39.8M |
GH, NTRA, CTKB, ADPT, AKYA
|
13F-HR |
11/14/2022, 02:45 PM |
| Q2 2022 |
9 |
$184M |
+$87.3M |
-$23.1M |
+$64.1M |
GH, NTRA, AKYA, ADPT, CTKB
|
13F-HR |
8/15/2022, 12:36 PM |
| Q1 2022 |
10 |
$211M |
+$94.2M |
|
+$94.2M |
NTRA, GH, CDNA, PACB, AKYA
|
13F-HR |
5/18/2022, 03:22 PM |
| Q4 2021 |
13 |
$327M |
+$97.7M |
-$3.43M |
+$94.2M |
NTRA, TMO, GH, CDNA, TECH
|
13F-HR |
2/14/2022, 02:49 PM |
| Q3 2021 |
23 |
$307M |
+$139M |
-$88.9M |
+$50.1M |
NTRA, CDNA, TMO, TECH, A
|
13F-HR |
11/15/2021, 04:18 PM |
| Q2 2021 |
21 |
$265M |
+$94.4M |
-$43M |
+$51.3M |
NTRA, CDNA, AMRSQ, TMO, NEO
|
13F-HR |
8/13/2021, 12:03 PM |
| Q1 2021 |
23 |
$204M |
+$35.2M |
-$18.8M |
+$16.4M |
AMRSQ, CDNA, NTRA, GH, EXAS
|
13F-HR |
5/14/2021, 01:56 PM |
| Q4 2020 |
21 |
$170M |
|
|
|
CDNA, NTRA, GH, CELL, AMRSQ
|
New Holdings |
5/14/2021, 01:59 PM |
| Q4 2020 |
11 |
$165M |
|
|
|
CDNA, NTRA, GH, CELL, AMRSQ
|
13F-HR |
2/16/2021, 05:11 AM |